Epigenetic Probes and Biomarkers in Disease Treatment and Screening [COVID-19]
Research type
Research Study
Full title
The Immunomodulatory Potential of Selective Jumonji Demethylase Inhibitor for the treatment of- and Characterisation of Microvesicles in Coronavirus Disease 2019 (COVID-19) and Other Disorders
IRAS ID
282507
Contact name
Richard Cohen
Contact email
Sponsor organisation
Joint Research Office, University College London
Duration of Study in the UK
4 years, 7 months, 25 days
Research summary
Coronavirus disease-19 (COVID-19) has been found to be associated with a severe inflammatory reaction, characterised by excessive activation of inflammatory cells and a consequent surge in pro-inflammatory mediators. Amongst the inflammatory cells activated in COVID-19 are macrophages. Macrophages are immune cells that reside within tissues and remain dormant until triggered to release a soup of pro-inflammatory mediators. Histones are modified during the activation of macrophages to allow for the expression of genes that code for these pro-inflammatory mediators. This study aims to assess the histone modifications that occur in macrophages during the course of the disease.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
21/NW/0023
Date of REC Opinion
15 Jan 2021
REC opinion
Favourable Opinion